Clinical trials
Therapy clinical trials
Below are recruiting therapy clinical trials, each written for real people, not researchers. We’re tracking 7,179 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06721936Recruiting
Study for menopause symptoms after breast cancer
This trial tests a treatment for menopause-like vaginal symptoms that can happen after breast cancer treatment. It aims to help survivors feel more comfortable.
MadridAges 38 years+ - NCT06947707Recruiting
Blood thinners for brain blood clot in Chinese patients
This trial tests two blood thinner medicines, edoxaban and rivaroxaban, in Chinese patients with a blood clot in a brain vein (cerebral venous thrombosis). It aims to see if these medicines are safe and work well.
Beijing, Beijing MunicipalityAges 18–80 - NCT06946615RecruitingPhase 1
Claudin18.2 cell therapy for advanced colorectal cancer
This study tests a new treatment using your own immune cells (called CAR-T and CAR-DC) that are engineered to attack cancer cells with a specific protein (Claudin18.2). It is for people with advanced colorectal cancer who have exhausted standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT05257629RecruitingPhase 3
Aggressive smoking quit program after heart problems
This trial tests whether a strong quit plan using varenicline (a quit pill) plus nicotine e-cigarettes, along with counseling, helps people stop smoking after a recent heart-related event. It’s aimed at people who want to quit and can safely stay involved for about a year.
New Westminster, British ColumbiaAges 18 years+ - NCT06322017Recruiting
Early vein isolation for atrial fibrillation in older adults
This study compares doing vein isolation soon after diagnosis versus usual care in people 75+ with new or early atrial fibrillation. The goal is to see if early treatment prevents the condition from getting worse and improves quality of life.
Nantes, Loire AtlantiqueAges 75 years+ - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT07177430Recruiting
Breathing muscle training for teens with scoliosis
This trial tests if special breathing exercises can help teens with scoliosis who are also doing Schroth therapy. It aims to strengthen the muscles that help you breathe.
Wroclaw, Lower Silesian VoivodeshipAges 11–16 - NCT07175025Recruiting
PTSD treatment for pregnant and new mothers
This study tests a new therapy to help pregnant women and new mothers with PTSD. The goal is to see if the therapy improves mental health after trauma.
Indianapolis, IndianaAges 18–50 - NCT07176767Recruiting
Sleep study on insomnia and mask use in kids
This study looks at how insomnia affects how well children and teenagers use their breathing mask (PAP therapy) for sleep apnea. It aims to find ways to help kids stick with their treatment.
Vancouver, British ColumbiaAges 8–18 - NCT07183657Recruiting
Tracking inhaler use in lung disease
This study looks at how well people with COPD or asthma use their inhalers. It aims to understand common problems and find ways to improve treatment adherence.
Hradec KrálovéAges 18 years+ - NCT07175480RecruitingPhase 2
Stopping treatment for kidney cancer based on PET/CT results
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
Nanjing, JiangsuAges 18 years+ - NCT07176312RecruitingPhase 2
Zanidatamab with pembrolizumab and chemo for HER2+ and PD-L1+ stomach cancer
This trial tests a new combination of targeted therapy (zanidatamab), immunotherapy (pembrolizumab), and chemotherapy for people with HER2-positive and PD-L1-positive advanced stomach or gastroesophageal cancer. It aims to see if this combination is more effective than current treatments.
BerlinAges 18 years+ - NCT07179926Recruiting
Impact of pasireotide on bone health in acromegaly
This trial studies how pasireotide LAR—a drug that controls growth hormone levels—affects bone health in people with acromegaly whose disease is not well-controlled after 6 months of another therapy. It may help patients understand the bone benefits of switching to this treatment.
Rome, RMAges 18 years+ - NCT07176988Recruiting
Voice therapy study for certain voice problems
This study tests a behavioral voice therapy approach for people with voice issues caused by muscle tension or benign vocal fold lesions. It aims to improve communication and requires participants to attend sessions and practice with a smartphone.
Atlanta, GeorgiaAges 16–65 - NCT07176182RecruitingPhase 2
Chemotherapy with alvenor for rectal cancer with high YWHAB
This trial tests adding the drug alvenor to standard chemotherapy before surgery for rectal cancer patients whose tumors have high levels of a protein called YWHAB. The goal is to see if this combination can improve treatment outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07178340RecruitingPhase 2
Perioperative therapy for HER2-negative stomach cancer
This trial tests a treatment given before and after surgery for a rare type of stomach cancer called hepatoid adenocarcinoma. It aims to improve outcomes for patients whose tumors are HER2-negative and have not spread too far.
BeijingAges 18–75 - NCT07183644Recruiting
Laser treatment for port-wine birthmarks in children
This study tests how well laser therapy works for children with port-wine stains (red or purple birthmarks). It aims to find the best way to use lasers to lighten or remove these marks safely.
Dallas, TexasAges 2 months–18 years - NCT07180693Recruiting
Breast cancer that returns after CDK4/6 inhibitor treatment
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
Bergamo, ItalyAges 18 years+ - NCT07180355RecruitingPhase 1
Gene therapy trial for Friedreich's ataxia
This trial tests a gene therapy called SGT-212 for people with Friedreich's ataxia. It aims to help treat the condition by delivering a working copy of the gene.
Los Angeles, CaliforniaAges 18–40 - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07177339RecruitingPhase 3
Testing depemokimab for COPD with type 2 inflammation
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
Newport Beach, CaliforniaAges 40–75 - NCT07178431RecruitingPhase 1/Phase 2
CAR T-cell therapy for worsening multiple sclerosis
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
BerlinAges 18–55 - NCT07174908RecruitingPhase 3
New drug combo vs standard therapy for KRAS G12C lung cancer
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
Beijing, Beijing MunicipalityAges 18–80
Hear when a new Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for therapy?
- Yes. Clin2 currently lists 7,179 recruiting therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.